Table 1 Main characteristics of all studies included in the meta-analysis for overall survival

From: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

Author

Patients Ki-67+/− (total)

Median FU (mos)

Systemic treatment

Antibody

Threshold (chosen by)

HR (95% CI)

Bevilacqua et al (1996)

94/13 (107)

74

Untreated

Anti-Ki-67 Anti-MIB-1

10% (arbitrary)

2.75 (1.02–7.39)

Bos et al (2003)

63/87 (150)

106 (mean)

N⩾4: CMF or TAM

Anti-Ki-67

10% (arbitrary)

2.47 (1.08–5.65)

Brown et al (1996)

170/504 (674)

72

156 CT and/or HT

Anti-Ki-67

5% (optimal cut-off)

1.19 (0.79–1.80)

Caly et al (2004)

122/122 (244)

72 (minimum)

Not reported

Anti-MIB-1

32% (proportion of scored cells)

1.95 (0.92–4.14)

Domagala et al (1996) N0

66/45 (111)

88

47 CT or HT

Anti-MIB-1

10% (median value)

3.04 (1.03–8.99)

Domagala et al (1996) N+

40/35 (75)

88

47 CT or HT

Anti-MIB-1

10% (median value)

1.38 (0.66–2.86)

Erdem et al (2005)

13/34 (47)

72.5

All adjuvant CT (?)

Anti-Ki-67

10% (median value)

17.23 (2.42–122.36)

Fresno et al (1997)

84/62 (146)

75

13 CMF 80 TAM

Anti-MIB-1

10% (arbitrary)

1.81 (0.71–4.59)

Gasparini et al (1994)

83/82 (165)

60

82 CMF and/or HT

Anti-Ki-67

7.5% (mean value)

2.58 (1.21–5.49)

Gonzalez et al (2003)

NR (221)

102.5

Not reported

Anti- MIB-1

30% (arbitrary)

3.18 (1.52–6.65)

Goodson et al (2000)

56/56 (112)

5.1 y

104 CT or HT

Anti- MIB-1

24% (mean value)

2.90 (1.18–7.15)

Heatley et al (2002)

26/33 (59)

5 y

Not reported

Anti-Ki-67

10% (mean value)

0.81 (0.36–1.81)

Hlupic et al (2004)

117/75 (192)

180 (for N+ patients)

Various adjuvant CT regimens (?)

Anti-Ki-67

10% (arbitrary)

1.30 (0.80–2.11)

Jacquemier et al (1998)

74/78 (152)

60

(?) FAC, FEC or FMC

Anti- MIB-1

3.5% (median value)

3.29 (1.49–7.22)

Jansen et al (1998)

153/168 (321)

128

(?) FAC

Anti-MIB-1

7% (median value)

1.35 (1.01–1.80)

Jensen et al (1995)

54/64 (118)

104

3 CT or HT

Anti-MIB-1

17% (median value)

3.41 (1.44–8.06)

Liu et al (2001)

389/384 (773)

16.3 y

268 CT (17% DOX)

Anti-MIB-1

17.8% (median value)

1.76 (1.41–2.20)

Locker et al (1992)

23/44 (67)

27

Not reported

Anti-Ki-67

9% (tertile distribution)

4.19 (1.19–14.7)

Mottolese et al (2000)

87/70 (157)

60

All EC

Anti-Ki-67

10% (arbitrary)

1.82 (0.90–3.67)

Pellikainen et al (2003)

184/230 (414)

57.2

(?) CMF and TAM or toremifene

Anti-MIB-1

20% (arbitrary)

2.56 (1.46–4.50)

Pierga et al (1996)

66/70 (136)

70

16 FAC/39 TAM

Anti-Ki-67

8% (median value)

1.37 (0.64–2.91)

Pietilainen et al (1996)

100/88 (188)

8.6 y (mean)

64 CT (?)

Anti-MIB-1

20% (arbitrary)

1.88 (1.16–3.05)

Pinder et al (1995)

74/103 (177)

NR

Untreated

Anti-MIB-1

34% (tertile distribution)

1.66 (1.09–2.52)

Pinto et al (2001)

136/159 (295)

39.6

201 CT/131 HT

Anti-Ki-67

10% (arbitrary)

1.46 (0.74–2.87)

Querzoli et al (1996)

43/127 (170)

66.5

Not reported

Anti-Ki-67 Anti-MIB-1

13% (tertile distribution)

2.05 (1.11–3.77)

Railo et al (1993)

37/289 (326)

2.7 y (mean)

Not reported

Anti-Ki-67

10% (nuclear staining)

2.39 (0.77–7.38)

Rudolph et al (1999a)

363/500 (863)

149.3

531 CT or HT

Anti-Ki-S11

25% (median values)

1.91 (1.50–2.44)

Rudolph et al (1999b)

137/234 (371)

95

86 TAM

Anti-Ki-S5

25% (median values)

4.88 (2.98–7.99)

Seshadri et al (1996)

235/472 (707)

66

(?) CMF or TAM

Anti-MIB-1

10% (arbitrary)

2.60 (1.80–3.75)

Thor et al (1999)

243/243 (486)

62

Not reported

Anti-MIB-1

28.6% (median value)

1.94 (1.04–3.61)

Trihia et al (2003) N0

61/127 (188)

13.5 y

125 CMF

Anti-MIB-1

16% (proportion of scored cells)

1.90 (1.18–3.08)

Trihia et al (2003) N+

82/164 (246)

13.5 y

246 CMF

Anti-MIB-1

16% (proportion of scored cells)

2.42 (1.71–3.41)

Tynninen et al (1999)

42/42 (84)

10.3 y (mean)

13 CT (?)

Anti-MIB-1

9.8% (median value)

1.05 (0.55–2.00)

Veronese et al (1995)

64/63 (127)

61

Not reported

Anti-Ki-67 Anti-MIB-1

14% (median value)

0.42 (0.20–0.87)

Weikel et al (1991)

78/115 (193)

23.6 (mean)

CMF and/or TAM

Anti-Ki-67

20% (proportion of scored cells)

3.42 (1.39–8.40)

Weikel et al (1995) N0

93/141 (234)

3.4 y (mean)

Mostly TAM

Anti-Ki-67

20% (groups)

1.66 (0.79–3.51)

Weikel et al (1995) N+

138/177 (315)

3.4 y (mean)

315 CMF and/or TAM

Anti-Ki-67

20% (groups)

2.36 (1.55–3.60)

Wintzer et al (1991)

32/31 (63)

37

Not reported

Anti-Ki-67

12% (median value)

2.51 (1.00–6.34)

  1. CI, confidence interval; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; CT, chemotherapy; DOX, doxorubicin; EC, epirubicin, cyclophosphamide; FAC, 5-fluorouracil, doxorubicin, cyclophosphamide; FEC, 5-fluorouracil, epirubicin, cyclophosphamide; FMC, 5-fluorouracil, mitoxantrone, cyclophosphamide; FU, follow-up; HR, hazard ratio; HT, hormonotherapy; mos, months; N0, node-negative; N+, node-positive; NR, not reported; TAM, tamoxifen; +, positive; −, negative; y, years.
Back to article page